Humira injection under the eye for keratoprosthesis
Treatments studied
Part of Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests whether injecting Humira (adalimumab) under the membrane of the eye can improve outcomes for people receiving a special type of artificial cornea called a Boston keratoprosthesis. It is for patients with severe corneal scarring and poor vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are scheduled or eligible for keratoprosthesis surgery due to severe corneal damage
- Your vision in the study eye is worse than 20/200, and your other eye sees worse than 20/40
- You can still sense light from the nasal side of your eye
- You are not pregnant or breastfeeding, and do not have active infections like tuberculosis or hepatitis B/C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of cornea transplant surgery (PKP and DSAEK) to see which one helps people with severe corneal swelling see better after two years. It may be an option if you have advanced bullous keratopathy and need a first-time cornea transplant.
This trial looks at whether a specific eye laser treatment done through the white of the eye (called transscleral cyclophotocoagulation) works well and is safe for people getting a Boston keratoprosthesis. It may help improve comfort and vision outcomes for selected patients needing this type of cornea/eye replacement surgery.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This trial tests a new artificial cornea device (keratoprosthesis) for people with severe corneal scarring or damage who cannot see well and are at high risk for corneal transplant failure. The goal is to restore vision and improve quality of life.
This trial tests infliximab—given as eye drops—after a first corneal transplant to see if it can improve healing and eye outcomes. It may help people at risk of inflammation after surgery, but it also requires careful screening for infection and medication safety.
This trial tests a new injectable medicine, Acthar Gel, for moderate to severe dry eye and eye pain linked to autoimmune disease. It aims to see if the drug can relieve these symptoms safely.
Hear when a new Stevens-Johnson Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.